No Data
No Data
Why Avita Medical, GenusPlus, Mesoblast, and Polynovo Shares Are Storming Higher
Jefferies Downgrades Mesoblast to Hold From Buy; Price Target Is AU$2.30
US FDA Approval of Mesenchymal Stromal Cell Therapy Bodes Well for Cynata Therapeutics, Euroz Hartleys Says
Why Bellevue Gold, Mesoblast, Pilbara Minerals, and Wesfarmers Shares Are Dropping Today
Why the Mesoblast Share Price Is Diving 18% After an FDA Win
Mesoblast Is Maintained at Overweight by Piper Sandler